about
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Plasma biomarkers for detecting Hodgkin's lymphoma in HIV patients.MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patientsImplementation of an analytical model for leakage neutron equivalent dose in a proton radiotherapy planning system.Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab VedotinOutcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile.Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.Current concepts and controversies in the management of early stage Hodgkin lymphoma.Hemorrhagic Cystitis due to BK Reactivation in a Young Female Treated for Hodgkin-Disease.Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution.Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradoxSerial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101Association of HHV-6 with Hodgkin and non Hodgkin lymphomaVery low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.In situ follicular lymphoma: pathologic characteristics and diagnostic features.Chemotherapy only for localized Hodgkin lymphoma.Characterization of HIV-associated Hodgkin's lymphoma in HIV-infected patients: a single-center experience.Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.The new therapeutical scenario of Hodgkin lymphoma.PET-directed therapy in Hodgkin lymphoma: Ready for prime time?Radiation-induced valvular heart disease.Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation.Erythrocyte and blood antibacterial defense.PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeThe continued conundrum of Hodgkin lymphoma etiology.Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey.ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.Hodgkin's lymphoma--long-term outcome: an experience from a tertiary care cancer center in North India.Hematological cancer: Localized non-bulky Hodgkin lymphoma--future questions.Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.
P2860
Q30538453-42CA45C7-DD3C-473B-93D3-F125530E2724Q33645331-E2443A9B-D172-485E-8883-624F10FFBF98Q33704061-2070CD6C-5A1B-44D4-9646-2767D5CDA515Q34110884-74DCED43-EF8A-4A43-B522-0B67CF5CAB2FQ34738140-A837F42A-0DEC-4630-B479-8BB4BC424254Q35237533-A4A2970B-99B5-49A5-BFF1-53E57428562AQ35650402-AAC362C5-A362-4BC5-BBF2-D2C78F069432Q35669134-26A335B6-2DC8-42CA-B8CF-C2912852BDE4Q35694050-B48439C7-E898-4367-AA57-33BF314EEC2BQ35865599-23ADAC68-F6E6-444C-A0DC-EF41B83CAAE1Q36061643-841CC312-C56C-4C72-9325-8D6EEE9A6406Q36169369-3C48118C-F791-4067-A00A-8D9243CACEAFQ36458013-05733763-981C-45A8-A236-729A4174E2CDQ36628996-516527CE-96A4-4F59-AB0C-EE8E0A2F3379Q36815253-FEED2E9E-E7F9-4678-A854-0CDCF61E1F49Q37001238-FD7A379C-041F-4B18-8F60-230A9BEB17A4Q37149757-81D8FE0F-F97F-455C-B0D2-D68663B14E34Q37874211-42F1CB4C-C960-4D80-B83A-57FE6B984C44Q37888802-B9B47FD3-F29A-4027-9437-2F82E70E9CBAQ37981081-B091EAE4-15BD-4C04-A83D-2C72716CE5D9Q38022455-2C5C8442-6D27-4FEC-B96E-365898D9F50CQ38164572-E2CBAB4A-37B3-4E6D-BECA-15A9D4DE7DE8Q38476250-3D925060-97B3-4C54-B5CC-31998397BCBEQ38513816-FD6A0409-C876-41BA-8EE1-415F69D2706FQ38608555-6D9C7C62-529D-49EE-AED5-F2CEC19B6156Q38667723-A7FC31A6-228F-4F04-B173-054618C0F3D9Q38677724-B3CFC722-D5ED-49E1-A1E3-24D4B8EA1244Q38795442-052AC544-911D-463D-8CFD-2D6C908D9BF7Q38881049-768B8C25-C9B3-4E27-A68C-5588D5C9F06FQ38955399-415F1354-7FC8-44B4-B2F7-31DE907CCDDAQ39829267-A1B62D65-56AC-4702-AAD8-D77262531FC7Q41069147-26C7E3DB-494E-4D31-922D-165B8E2C380BQ41735742-8A7EB078-FA80-41B3-8905-308A457AF81FQ50873125-B0F760B5-7EB7-4A5D-B0F6-D945BC99C010Q51298132-EF2724BC-DD5B-410E-A95F-1B4FA64CC869Q51456724-87AFC871-00BC-4AF4-9D57-97E5B885C6FBQ51634271-2C50F65E-2CF5-4020-AD4A-7195BD36A443Q52715715-930CFFE8-0E6D-401A-B1CB-F8CD3D1EAAF3
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Early-stage Hodgkin's lymphoma.
@ast
Early-stage Hodgkin's lymphoma.
@en
Early-stage Hodgkin's lymphoma.
@nl
type
label
Early-stage Hodgkin's lymphoma.
@ast
Early-stage Hodgkin's lymphoma.
@en
Early-stage Hodgkin's lymphoma.
@nl
prefLabel
Early-stage Hodgkin's lymphoma.
@ast
Early-stage Hodgkin's lymphoma.
@en
Early-stage Hodgkin's lymphoma.
@nl
P356
P1476
Early-stage Hodgkin's lymphoma.
@en
P304
P356
10.1056/NEJMRA1003733
P407
P577
2010-08-01T00:00:00Z